EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Engineering a HER2-CAR-NK Cell Secreting Soluble Programmed Cell Death Protein with Superior Antitumor Efficacy

Wenjiao Xia, Jiaxin Chen, Wenqing Hou, Junsheng Chen iD, Ying Xiong iD, Hongyan Li iD, Xin Qi, Hui Xu, Zuoquan Xie, Mingfeng Li, Xiaomin Zhang, Jing Li

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms24076843 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Wenjiao Xia und 11 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Marine Drugs, Chinese Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, Laboratory for Marine Drug…. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Hainan Provincial Joint Project of Sanya Yazhou Bay Science and Technology City, Shandong Provincial Natural Science Foundation (major basic research projects).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A new therapy strategy for relapsing patients who have received trastuzumab treatment urgently needs to be explored. HER2-specific chimeric antigen receptor (CAR)-expressing NK cells are being rapidly developed for solid tumor therapy, as they have many advantages over HER2-CAR-T cells. Endogenous soluble PD-1 (sPD-1) from the PD-1 extracellular domain blocks PD-1/PD-L1 interaction to promote cancer immunology. Herein, we engineered a new HER2-CAR-NK cell that co-expresses sPD-1 (designed as sPD-1-CAR-NK cells) and assessed its cytotoxic activities toward various cancer cells, activation of immunity and sPD-1 release in vitro and in mouse models bearing breast cancer cells with high HER2 expression, with or without trastuzumab resistance. We demonstrated that sPD-1-CAR-NK cells were able to release bioactive sPD-1, thereby enhancing the cytolytic activities of HER2-CAR-NK cells against HER2 and PD-L1 highly expressing target cells accompanied by increases in the secretion of perforin, granzyme B and IFN-γ. In vivo, sPD-1-CAR-NK cells had superior immunological anticancer efficacy compared to HER2-CAR-NK cells, and they had advantages over HER2-CAR-NK cells in the intraperitoneal injection of sPD-1. Moreover, the infiltration and activation of NK and T cells into tumor tissue were increased in mice with sPD-1-CAR-NK cells. There was no significant change in the body temperature, organ tissue and body weight in all groups except for the group with the PD-1 injection. Together, these data indicate that HER2-specific sPD-1-CAR-NK cells can transport sPD-1 into cancer tissues with high HER2 expression, further improving the efficacy of HER-CAR-NK cells without obvious side effects. sPD-1-CAR-NK is a promising cytotherapeutic agent for patients bearing HER2-positive breast cancer, including those with trastuzumab resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Chimeric AntigenAnimalsMiceB7-H1 AntigenCell Line, TumorProgrammed Cell Death 1 ReceptorNeoplasm Recurrence, LocalKiller Cells, NaturalTrastuzumabXenograft Model Antitumor AssaysImmunotherapy, Adoptive

Stichwörter der Autor:innen

NK cellsbreast cancerschimeric antigen receptorcytotherapysPD-1

Substanzen

Receptors, Chimeric AntigenB7-H1 AntigenProgrammed Cell Death 1 ReceptorTrastuzumab

Autor:innen und Institutionen

  • Key Laboratory of Marine Drugs, Chinese Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, Laboratory for Marine Drugs and Bioproducts of Qingdao National Laboratory for Marine Science an…
  • School of Pharmacy, Fudan University, Shanghai, 201203, China.
  • State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai, 200126, China.

ORCID-Profile: Junsheng Chen, Ying Xiong, Hongyan Li

Förderung

  • National Natural Science Foundation of China
  • Hainan Provincial Joint Project of Sanya Yazhou Bay Science and Technology City
  • Shandong Provincial Natural Science Foundation (major basic research projects)

Zitieren

APA

Xia, W., Chen, J., Hou, W., Chen, J., Xiong, Y., Li, H., Qi, X., Xu, H., Xie, Z., Li, M., Zhang, X., & Li, J. (2023). Engineering a HER2-CAR-NK Cell Secreting Soluble Programmed Cell Death Protein with Superior Antitumor Efficacy. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24076843

Vancouver

Xia W, Chen J, Hou W, Chen J, Xiong Y, Li H, et al. Engineering a HER2-CAR-NK Cell Secreting Soluble Programmed Cell Death Protein with Superior Antitumor Efficacy. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24076843

BibTeX
@article{Xia2023,
  author = {Xia, Wenjiao and Chen, Jiaxin and Hou, Wenqing and Chen, Junsheng and Xiong, Ying and Li, Hongyan and Qi, Xin and Xu, Hui and Xie, Zuoquan and Li, Mingfeng and Zhang, Xiaomin and Li, Jing},
  title = {Engineering a HER2-CAR-NK Cell Secreting Soluble Programmed Cell Death Protein with Superior Antitumor Efficacy},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms24076843}
}
Kostenlos starten →